

Lanzotyle 15 Tablet

Product Information: Lansoprazole (15 mg) Tablet

Composition

- **Lansoprazole: 15 mg per tablet.**
-

Pharmacological Class

- **Class: Proton pump inhibitor (PPI).**
 - **Mechanism of Action: Lansoprazole works by inhibiting the proton pump (H⁺/K⁺ ATPase) in the stomach lining, which is responsible for the final step in the production of gastric acid. By reducing stomach acid production, Lansoprazole helps alleviate symptoms and promotes healing in conditions involving excessive acid secretion.**
-

Indications

Lansoprazole (15 mg) is indicated for the treatment and prevention of various gastrointestinal disorders, including:

1. **Gastroesophageal Reflux Disease (GERD): Treatment of symptoms and healing of erosive esophagitis caused by acid reflux.**
2. **Peptic Ulcers: Management of active duodenal and gastric ulcers, including ulcers caused by Helicobacter pylori infection (as part of combination therapy).**

3. **Helicobacter pylori Eradication: As part of combination therapy to eradicate H. pylori and reduce the risk of duodenal ulcer recurrence.**
 4. **Zollinger-Ellison Syndrome: Long-term management of hypersecretory conditions like Zollinger-Ellison syndrome.**
 5. **Erosive Esophagitis: Healing of moderate to severe esophagitis caused by acid reflux.**
 6. **Prevention of NSAID-induced Ulcers: Prophylaxis against ulcers in patients taking non-steroidal anti-inflammatory drugs (NSAIDs).**
-

Dosage and Administration

- **Adults:**
 - **For GERD: 15 mg once daily, typically taken in the morning before a meal. Duration of therapy may vary (usually 4 to 8 weeks).**
 - **For Peptic Ulcers: 15 mg to 30 mg once daily. Treatment duration is typically 4 to 8 weeks depending on the severity.**
 - **For H. pylori eradication: 15 mg once or twice daily in combination with appropriate antibiotics.**
 - **For Zollinger-Ellison Syndrome: The dosage is individualized, generally starting with 30 mg once or twice daily, adjusted as needed.**

- For NSAID-induced Ulcers: 15 mg to 30 mg once daily during NSAID therapy.
 - **Pediatric Patients:**
 - For GERD and other acid-related conditions: Dosage is based on weight. Typically, the dose ranges from 15 mg to 30 mg per day. Consult pediatric dosing guidelines for specific recommendations.
 - **Route of Administration: Oral.** Lansoprazole tablets should be swallowed whole and not chewed or crushed.
-
4. **Hypomagnesemia:** Long-term PPI therapy has been associated with low magnesium levels, which may lead to muscle spasms, arrhythmias, or seizures.
 5. **Liver Disease:** Use with caution in patients with severe liver impairment, as the drug is metabolized in the liver. Dosage adjustments may be needed.
 6. **Risk of Rebound Acid Hypersecretion:** Sudden discontinuation after prolonged use may result in rebound acid hypersecretion.

Contraindications

- Hypersensitivity to Lansoprazole or any other component of the tablet.
- Concomitant use with atazanavir (an HIV medication), due to reduced efficacy of atazanavir when combined with proton pump inhibitors.

Warnings and Precautions

1. **Clostridium difficile-associated Diarrhea:** Proton pump inhibitors like Lansoprazole may increase the risk of Clostridium difficile infection, particularly in hospitalized patients.
2. **Bone Fracture Risk:** Long-term use of PPIs may increase the risk of fractures, especially in individuals with other risk factors for osteoporosis.
3. **Vitamin B12 Deficiency:** Prolonged use (more than 3 years) may lead to Vitamin B12 deficiency due to reduced stomach acid.

Adverse Effects

- **Common:**
 - Headache, diarrhea, abdominal pain, nausea, dizziness, constipation, and flatulence.
- **Serious:**
 - Hypersensitivity reactions (e.g., rash, pruritus, angioedema), liver enzyme abnormalities, blood disorders (e.g., thrombocytopenia), and severe diarrhea due to C. difficile infection.
 - Bone fractures, especially with prolonged high-dose use or in patients with risk factors for osteoporosis.
 - Kidney issues: Interstitial nephritis, acute kidney injury, and chronic kidney disease in rare cases.

Drug Interactions

- **Clopidogrel:** Lansoprazole may reduce the effectiveness of clopidogrel (an antiplatelet drug) by inhibiting its activation. Alternative treatments may be considered.
- **Antiretroviral Drugs:** Lansoprazole may interfere with the absorption of certain HIV medications (e.g., atazanavir, rilpivirine).
- **Warfarin:** Lansoprazole may enhance the anticoagulant effect of warfarin, increasing the risk of bleeding. Regular monitoring of INR levels is advised.
- **Diazepam:** Lansoprazole may increase the serum concentration of diazepam, leading to enhanced sedation and adverse effects.
- **Methotrexate:** Lansoprazole may increase methotrexate levels, especially when used in high doses. Monitor closely when using methotrexate with Lansoprazole.

Storage Instructions

- Store at room temperature (below 30°C), away from moisture and heat.
- Keep the container tightly closed.
- Do not use the medication past its expiration date.

Clinical Benefits

- **Effective for acid suppression:** Lansoprazole is highly effective in reducing gastric acid production, which helps in the management of acid-related gastrointestinal conditions.
- **Versatile treatment:** Used in a wide range of conditions, from heartburn

to complex gastric ulcers and H. pylori eradication.

- **Improves quality of life:** Provides relief from symptoms of GERD, ulcers, and other acid-related conditions, improving patients' overall well-being.

Packaging

- Lansoprazole (15 mg) tablets are available in blister packs or bottles containing 10, 14, 30, or 100 tablets, depending on the brand and manufacturer.

Lansoprazole (15 mg) Tablet is a highly effective proton pump inhibitor used for managing acid-related conditions such as GERD, ulcers, and H. pylori infections. It offers fast and lasting relief from symptoms and helps promote the healing of the stomach and esophagus lining.

Manufactured in India for:

CafoliTM
L I F E C A R E

Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for